0000950170-23-043554.txt : 20230821 0000950170-23-043554.hdr.sgml : 20230821 20230821070015 ACCESSION NUMBER: 0000950170-23-043554 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230821 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20230821 DATE AS OF CHANGE: 20230821 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Renalytix plc CENTRAL INDEX KEY: 0001811115 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39387 FILM NUMBER: 231187305 BUSINESS ADDRESS: STREET 1: FINSGATE STREET 2: 5-7 CRANWOOD STREET CITY: LONDON STATE: X0 ZIP: EC1V 9EE BUSINESS PHONE: 44 29 2071 0570 MAIL ADDRESS: STREET 1: FINSGATE STREET 2: 5-7 CRANWOOD STREET CITY: LONDON STATE: X0 ZIP: EC1V 9EE FORMER COMPANY: FORMER CONFORMED NAME: Renalytix AI plc DATE OF NAME CHANGE: 20200430 8-K 1 rnlx-20230821.htm 8-K 8-K
false0001811115trueX000-00000000001811115rnlx:AmericanDepositarySharesMember2023-08-212023-08-2100018111152023-08-212023-08-21

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 21, 2023

 

Renalytix plc

(Exact name of registrant as specified in its Charter)

 

England and Wales

001-39387

Not Applicable

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

Finsgate

5-7 Cranwood Street

London EC1V 9EE

United Kingdom

(Address of principal executive offices) (Zip Code)

 

+44 20 3139 2910
(Registrant’s telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading
Symbol(s)

Name of each exchange
on which registered

Ordinary shares, nominal value £0.0025 per share

n/a

The Nasdaq Stock Market LLC*

American Depositary Shares, each representing two ordinary shares, nominal value £0.0025 per share

RNLX

The Nasdaq Stock Market LLC

 

* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 7.01. Regulation FD Disclosure.

Renalytix has been notified that KidneyIntelX™ is included in the draft Kidney Disease Improving Global Outcomes (KDIGO) 2023 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (the "KDIGO 2023 Guideline"). KDIGO guideline development follows an explicit process to translate global scientific evidence review and appraisal into practical recommendations for clinicians and patients. A 30 day open public comment period on the draft KDIGO 2023 guidelines that began in July is now closed, and the final version of these kidney disease guidelines is expected to be released in the fourth quarter of 2023.

The KDIGO 2023 Guideline is a comprehensive update of the current KDIGO guideline for kidney disease evaluation and management issued in 2012. The aim of the update is to generate a useful resource that clearly and concisely addresses relevant questions with actionable recommendations based on a formal evidence review and consensus-based practice points to guide clinical practice. Guideline recommendations were based on systematic reviews of relevant clinical trials and publications. Appraisal of the quality of the evidence and the strength of recommendations for graded recommendations followed the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.

Renalytix believes that inclusion of KidneyIntelX in the KDIGO 2023 Guideline would be significant for broader adoption, clinical acceptance, and reimbursement of KidneyIntelX testing for risk assessment of patients with type 2 diabetes and early-stage kidney disease in the United States and abroad.

KDIGO is a global non-profit organization developing and implementing evidence-based clinical practice guidelines in kidney disease that are followed by clinicians in the United States and around the world. It is an independent, foundation incorporated in Belgium and accountable to the public and the patients it serves. KDIGO has a network of dedicated volunteers from around the world who promote awareness, dissemination, adoption, and clinical integration of KDIGO Guidelines both globally and in their respective countries or regions.

The information contained in this Item 7.01 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and such information is not incorporated by reference into any registration statements or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language contained in such filing, except as shall be expressly set forth by specific reference to this filing.

 

 

Forward Looking Statements

Statements contained in this Current Report on Form 8-K regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning: the potential for KidneyIntelX to be included in the final KDIGO 2023 Guidelines, the commercial prospects of KidneyIntelX and kidneyintelX.dkd, including whether KidneyIntelX and kidneyintelX.dkd will be successfully adopted by physicians, inform clinical guidelines, achieve expanded insurance coverage and be successfully distributed and marketed, the potential for KidneyIntelX and kidneyintelX.dkd to be expanded and approved for additional indications and in additional jurisdictions, our expectations regarding reimbursement decisions and the ability of KidneyIntelX and kidneyintelX.dkd to curtail costs of chronic and end-stage kidney disease, optimize care delivery and improve patient outcomes. Words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “seeks,” and similar expressions are intended to identify forward-looking statements. We may not actually achieve the plans and objectives disclosed in the forward-looking statements, and you should not place undue reliance on our forward-looking statements. Inclusion of KidneyIntelX in the draft KDIGO guidelines does not guarantee inclusion in the final guidelines. Any forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others: that KidneyIntelX and kidneyintelX.dkd are based on novel artificial intelligence technologies that are rapidly evolving and potential acceptance, utility and clinical practice remains uncertain; we have only recently commercially launched KidneyIntelX; and risks relating to the impact on our business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in our filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” section of our annual report on Form 20-F filed with the SEC on October 31, 2022, and other filings we make with the SEC from time to time. All information in this Current Report on Form 8-K is as of the date of the release, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

renalytix plc

 

 

 

Dated: August 21, 2023

By:

/s/ James McCullough

 

 

James McCullough
Chief Executive Officer

 

 

 EX-101.SCH 2 rnlx-20230821.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 3 rnlx-20230821_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 4 rnlx-20230821_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document Information [Table] Pre-commencement Issuer Tender Offer No Trading Symbol Flag Entity Address, State or Province Trading Symbol Soliciting Material Entity Address, City or Town Written Communications American Depositary Shares [Member] American Depositary Shares. Entity Central Index Key Entity Tax Identification Number Entity Registrant Name Entity Ex Transition Period Entity Information, Former Legal or Registered Name Entity [Domain] Document Period End Date Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Local Phone Number City Area Code Document Information [Line Items] Pre-commencement Tender Offer Cover [Abstract] Security Exchange Name Legal Entity [Axis] Entity Emerging Growth Company Amendment Flag Securities Act File Number Entity Address, Address Line Two Entity Address, Address Line One Title of 12(b) Security Entity Address, Country Document Type EX-101.DEF 5 rnlx-20230821_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document And Entity Information
Aug. 21, 2023
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 21, 2023
Entity Registrant Name Renalytix plc
Entity Central Index Key 0001811115
Entity Emerging Growth Company true
Entity Ex Transition Period false
Securities Act File Number 001-39387
Entity Incorporation, State or Country Code X0
Entity Tax Identification Number 00-0000000
Entity Address, Address Line One Finsgate
Entity Address, Address Line Two 5-7 Cranwood Street
Entity Address, City or Town London EC1V 9EE
Entity Address, Country GB
Entity Address, Postal Zip Code EC1V 9EE
City Area Code +44
Local Phone Number 20 3139 2910
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Ordinary shares, nominal value £0.0025 per share
No Trading Symbol Flag true
Security Exchange Name NASDAQ
American Depositary Shares [Member]  
Document Information [Line Items]  
Title of 12(b) Security American Depositary Shares, each representing two ordinary shares, nominal value £0.0025 per share
Trading Symbol RNLX
Security Exchange Name NASDAQ
XML 7 rnlx-20230821_htm.xml IDEA: XBRL DOCUMENT 0001811115 rnlx:AmericanDepositarySharesMember 2023-08-21 2023-08-21 0001811115 2023-08-21 2023-08-21 false 0001811115 true X0 00-0000000 8-K 2023-08-21 Renalytix plc 001-39387 Finsgate 5-7 Cranwood Street London EC1V 9EE EC1V 9EE GB +44 20 3139 2910 false false false false Ordinary shares, nominal value £0.0025 per share NASDAQ American Depositary Shares, each representing two ordinary shares, nominal value £0.0025 per share RNLX NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^0"X99K>]9!:G7&BN"^)]NK+NY *W3"W\RQ+50/>I"MJ(-.)_#1EZA$VY8<1(86> MY4)88TS<;_3\1C0>09:'[L#TA(XA+@W#"CTN*+N@U6/@24DM0H#E>QV3N7TR@ZN M6>1>9!CG*(.XLH/P4:V%&@/8-SF0!)?DJG547>EYIM[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E% M9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1,)KM\,<'AT_@%02P,$% @ !S@55V60>9(9 0 SP, !, !;0V]N M=&5N=%]4>7!E&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !8T\:J_Z3 M9UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB'2)XKK0A M.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T.EY&TWP39G 8ED\C<+, M:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM 2D9#L9&)7J5C ME>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\P68* MR,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B6.;/ M^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4 " '.!57!T%- M8H$ "Q $ @ $ 9&]C4')O<',O87!P+GAM;%!+ M 0(4 Q0 ( 97)PC$ 8 )PG 3 M " &UL4$L! A0#% M @ !S@55ZM5UZX(!0 =A4 !@ ("!# @ 'AL+W=O&UL4$L! A0#% @ !S@5 M5Y>*NQS $P( L ( !)A %]R96QS+RYR96QS4$L! M A0#% @ !S@55SJJHN= 0 / ( \ ( !#Q$ 'AL M+W=O7!E&UL4$L%!@ ) D /@( *L4 $! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 2 25 1 false 1 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports rnlx-20230821.htm rnlx-20230821.xsd rnlx-20230821_def.xml rnlx-20230821_lab.xml rnlx-20230821_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "rnlx-20230821.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 27 }, "contextCount": 2, "dts": { "definitionLink": { "local": [ "rnlx-20230821_def.xml" ] }, "inline": { "local": [ "rnlx-20230821.htm" ] }, "labelLink": { "local": [ "rnlx-20230821_lab.xml" ] }, "presentationLink": { "local": [ "rnlx-20230821_pre.xml" ] }, "schema": { "local": [ "rnlx-20230821.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 33, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 5, "total": 5 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 1, "memberStandard": 0, "nsprefix": "rnlx", "nsuri": "http://www.renalytixalplc.com/20230821", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "rnlx-20230821.htm", "contextRef": "C_771538c0-c86c-4e15-8a7a-f64c064c57db", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "rnlx-20230821.htm", "contextRef": "C_771538c0-c86c-4e15-8a7a-f64c064c57db", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 1, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "trueItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "rnlx_AmericanDepositarySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "American Depositary Shares.", "label": "American Depositary Shares [Member]" } } }, "localname": "AmericanDepositarySharesMember", "nsuri": "http://www.renalytixalplc.com/20230821", "presentation": [ "http://www.renalytixalplc.com/20230821/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0000950170-23-043554-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-043554-xbrl.zip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